Topical diltiazem for ulceration of striae distensae associated with bevacizumab therapy

Dermatol Ther. 2019 Jan;32(1):e12750. doi: 10.1111/dth.12750. Epub 2018 Oct 21.

Authors

Raquel Cabrera Fuentes¹, Jose Bernabeu Wittel¹, Palma Solano Paez², Concepcion Alvarez Vayo³, Julian Conejo Mir¹

Affiliations

¹ Department of Dermatology, Virgen del Rocio University Hospital, Seville, Spain.
² Department of Pediatrics, Virgen del Rocio University Hospital, Seville, Spain.
³ Pharmacy Department, Virgen del Rocio University Hospital, Seville, Spain.

PMID: 30238587
DOI: 10.1111/dth.12750

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Administration, Cutaneous
Adrenal Cortex Hormones / adverse effects
Antineoplastic Agents, Immunological / adverse effects*
Astrocytoma / drug therapy*
Astrocytoma / pathology
Bevacizumab / adverse effects*
Brain Neoplasms / drug therapy*
Brain Neoplasms / pathology
Child
Diltiazem / administration & dosage*
Humans
Skin / drug effects*
Skin / pathology
Skin Ulcer / chemically induced
Skin Ulcer / drug therapy*
Skin Ulcer / pathology
Striae Distensae*
Treatment Outcome
Vasodilator Agents / administration & dosage*
Wound Healing

Substances

Adrenal Cortex Hormones
Antineoplastic Agents, Immunological
Vasodilator Agents
Bevacizumab
Diltiazem